09:07:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-29 Ordinarie utdelning CIRCA 0.00 NOK
2024-05-28 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning CIRCA 0.00 NOK
2023-05-25 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning CIRCA 0.00 NOK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-03-02 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-17 Ordinarie utdelning CIRCA 0.00 NOK
2021-06-16 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-03-02 Bokslutskommuniké 2020

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Circa Group är verksamma inom bioteknik. Bolaget är en utvecklare av biokemikalier som vidare används för omvandling av avfallsmassa till diverse biokemiskt material. Tekniken används inom energisektorn vid olika produktionsprocesser. Bolaget grundades under 2006 och innehar störst verksamhet runtom den europeiska marknaden. Circa Group har sitt huvudkontor i Oslo, Norge.
2023-02-28 07:00:00
OSLO, NORWAY - 28 FEBRUARY 2023 - Circa Group AS (stock symbol: CIRCA) today
announced a strategic technology partnership with EKATO.

The agreement that has been signed with EKATO will see Circa incorporate EKATO's
hydrogenation technology in the development of its ReSolute plant, which will be
commissioned in June 2024. The partnership also covers future commercial scale
plants including FC6, which is in the planning stages.

EKATO Group is the market leader in hydrogenation technology, which plays a
critical role in the production of CyreneTM, Circa's flagship bio-based solvent.

EKATO RMT GmbH CEO Philip Mathon said: "At EKATO, we have a great strategic
interest to cooperate with companies developing innovative processes for
production of bio-based chemicals and materials. This long-term cooperation
agreement with CIRCA, is therefore, very important to us. As the leading process
loop solution provider in hydrogenation technology, we contribute with our
long-standing know-how and expertise from engineering to equipment to process
solution so as to ensure that CIRCA's production process captures the synergies
of sustainability and profit."

Circa Group AS CEO Tony Duncan said "Our contracts with major vendors are a
significant milestone as we progress towards the commissioning of ReSolute. By
partnering with global leaders of the chemical industry like EKATO, Circa is
gaining access to high calibre skills and the latest technology. This strategic
partnership positions Circa to work with the best in the field, as we execute
our vision to produce 80,000 tonnes of CyreneTM by 2030."


About Circa
Established in 2006, Circa Group converts sustainable, non-food biomass into
advanced bio-based chemicals with its proprietary FuracellTM process. Its
developing product portfolio includes flavours, biopolymers, and bio-solvents
including CyreneTM. By creating renewable chemicals from cellulose, Circa is
extracting value from non-food biomass and addressing a gap in the market by
providing bio-based, less carbon intensive alternatives, contributing to a more
circular economy.
https://circa-group.com


Investor Contact
Tone Leivestad
Chief Financial Officer
Circa Group AS
tone.leivestad@circa-group.com
Tel: +47 406 39 455

Media Contact
Amanda Keogh
General Manager Marketing and Sustainability
Circa Group AS
Amanda.keogh@circa-group.com
Tel: +61 407 275 126